Nevertheless, using various combinations of inhibitors of SGLT2 and agonists of GLP-1 receptor is currently under investigation to test whether this approach would yield better therapeutic outcomes in T1DM patients. Here, GLP1R is linked to type 1 diabetes mellitus.